ArticleACS infectious diseases2018
Pharmacokinetics of β-Lactam Antibiotics: Clues from the Past To Help Discover Long-Acting Oral Drugs in the Future.
Article in ACS infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Do dietary interventions exert clinically important effects on the bioavailability of β-lactam antibiotics? A systematic review with meta-analyses.The Journal of antimicrobial chemotherapy · 2024Pooled it
- Pharmacokinetics in Patients with Cystic Fibrosis: A Systematic Review of Data Published Between 1999 and 2019.Clinical pharmacokinetics · 2020Pooled it
- Bioactive peptides in Endodontic infections: The Good, The Bad, and The Ugly.Probiotics and antimicrobial proteins · 2026Review
- Acute Generalized Exanthematous Pustulosis: An Integrated Study of 503 Cases with Emphasis on Drug Culprits, Clinical Features, Diagnosis and Treatment.Journal of inflammation research · 2026Article
- Sanfetrinem, an oral β-lactam antibiotic repurposed for the treatment of tuberculosis.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2025Article
- A high-resolution screen identifies a preexisting beta-lactam that specifically treats Lyme disease in mice.Science translational medicine · 2025Article
- Sanfetrinem, an oral β-lactam antibiotic repurposed for the treatment of tuberculosis.bioRxiv : the preprint server for biology · 2024Article
- Antibiotics: From Mechanism of Action to Resistance and Beyond.Indian journal of microbiology · 2024Review
- Evaluating the efficacy of different antibiotics against Neisseria gonorrhoeae: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.BMC infectious diseases · 2024Article
- Optimizing tylosin dosage for co-infection ofFrontiers in pharmacology · 2023Article
- Pharmacokinetics of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase 1, Open-Label Study of Healthy Adults.Antimicrobial agents and chemotherapy · 2022Article
- Strongly Bactericidal All-Oral β-Lactam Combinations for the Treatment of Mycobacterium abscessus Lung Disease.Antimicrobial agents and chemotherapy · 2022Article
- Thermal and Microwave-Assisted Synthesis of New Highly Functionalized Bis-β-lactams from Available Compounds via Bisketene as an Intermediate.ACS omega · 2022Article
- An Iterative Approach Guides Discovery of the FabI Inhibitor Fabimycin, a Late-Stage Antibiotic Candidate withACS central science · 2022Article
- Identification of β-Lactams Active againstACS infectious diseases · 2022Article
- Review
- Solvent directed chemically divergent synthesis of β-lactams and α-amino acid derivatives with chiral isothiourea.Chemical science · 2022Article
- Effect of C-2 substitution on the stability of non-traditional cephalosporins in mouse plasma.The Journal of antibiotics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
β-Lactams represent perhaps the most important class of antibiotics yet discovered. However, despite many years of active research, none of the currently approved drugs in this class combine oral activity with long duration of action. Recent developments suggest that new β-lactam antibiotics with such a profile would have utility in the treatment of tuberculosis. Consequently, the historical β-lactam pharmacokinetic data have been compiled and analyzed to identify possible directions and drug discovery strategies aimed toward new β-lactam antibiotics with this profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.